Compare Eli Lilly And Co (LLY) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Shell PLC — how do they compare? Eli Lilly And Co trades at $1,176.32 (market cap $1.04T), while Shell PLC trades at $100.17 (market cap $284.34B). The key difference: Eli Lilly And Co is far larger — about 3.7× Shell PLC's market cap, and Shell PLC pays the higher dividend (3.12%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Shell PLC for 90 Days on average.
| LLY | SHEL | |
|---|---|---|
Market Cap | $1.04T | $284.34B |
Volume | 3,064,878 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $1.28K | $100.20 |
52-Week Low | $799.57 | $70.31 |
Typical Hold Time | 93 Days | 90 Days |
Enterprise Value | $1.09T | $326.04B |
Dividend Yield | 0.59% | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Shell (SHEL) trades at $100.56, up 3.83% today, approaching its 52-week high. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows bullish technical signals, supported by strong cash flow and a 61.5% analyst buy rating. Key developments include the LNG Canada Phase 2 expansion, doubling export capacity, and new carbon capture deals, highlighting strategic growth in energy transition assets.
Outlook remains positive with valuation metrics like P/E of 11.08 and EV/EBITDA of 4.8 suggesting room for upside toward the $102.53 consensus target. Risks include volatile oil prices and execution challenges in new projects, but robust LNG demand and portfolio optimization provide a solid foundation for investor returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
